SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19

• Published in: Clinical chemistry (Baltimore, Md.) Vol. 68; no. 1; pp. 204 - 213
• Main Authors: Wang, Hannah, Hogan, Catherine A, Verghese, Michelle, Solis, Daniel, Sibai, Mamdouh, Huang, ChunHong, Röltgen, Katharina, Stevens, Bryan A, Yamamoto, Fumiko, Sahoo, Malaya K, Zehnder, James, Boyd, Scott D, Pinsky, Benjamin A
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 30.12.2021
• Subjects: Antigenemia; Antigens; Antigens, Viral - blood; Coronavirus Nucleocapsid Proteins - blood; Coronaviruses; COVID-19; COVID-19 - diagnosis; COVID-19 Testing - methods; Diabetes mellitus; Diagnosis; Electrochemical Techniques; Electrochemiluminescence; Hospitalization; Humans; Hypertension; Immunoassay; Intensive care; Luminescent Measurements; Medical diagnosis; Nucleic acids; Nucleocapsid; Nucleocapsids; Patients; Phosphoproteins - blood; Plasma; Respiratory diseases; SARS-CoV-2; Sensitivity and Specificity; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Viral diseases
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1093/clinchem/hvab216

Abstract Background Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. Methods We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2–negative individuals. We used Kruskal–Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. Results Plasma antigen had 91.9% (95% CI 83.2%–97.0%) clinical sensitivity and 94.2% (84.1%–98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (Ct) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log10 fg/mL) was 5.4 (interquartile range 3.9–6.0) in outpatients, 6.0 (5.4–6.5) in inpatients, and 6.6 (6.1–7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2–6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. Conclusions SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.